At BioStrategies, we are all about delivery of biologics – delivering therapeutic proteins to cells throughout the body; to the brain; & to bone and connective tissue. We were created to solve the problem biological barriers present when treating metabolic disorders. Our platform provides breakthrough advantages in biodistribution and transport of molecules, demonstrating correction to CNS and the musculoskeletal system in our tested indications. Having already been granted Orphan Drug Designation by FDA for one of our lead products, our proprietary technology is positioned to seed a breakthrough biologic when it reaches the market.

Emeritus Professor of Biology

Biotechnology research in plant-based bioproduction of vaccine components and therapeutic proteins; protein processing; protein trafficking.

• Led start-up of new 89,000 ft2 state-of-the-art research building including design and equipping of research instrumentation and support facilities in research animal care, advanced microscopy, mammalian cell biology, immunology, plant transformation, plant growth & propagation, and analytics. • Developed and communicated Institute’s vision and defined research clusters building on existing strengths of ASU, the host institution, and priorities of the statewide ABI research consortium. • Grew ABI from 3 support staff in summer of 2004 to a highly energized and interactive research institute comprising more than 150 researchers and staff that includes 20 PIs/research groups. • Created a collaborative cross-disciplinary research environment that has served to drive discovery and successfully attract innovative dynamic researchers to A-State; fostered team-based research projects bringing innovative approaches to important regional and global challenges.

• Encompasses 5 universities and more than 40 faculty in plant biology, bioinformatics, bioengineering, food science, and agriculture. • Research is focused on metabolomics, biological set-points limiting protein, phytochemical, and biomass production, and impacts of plant products on other organisms (from microbes to mammals).

CropTech Corp. , co-founded by Drs. Carole Cramer and David Radin, was an emerging leader in biotech manufacturing. At the time of Cramer's exit, it was commercializing its patented protein manufacturing technology, which uses specially prepared tobacco plants as molecular “factories” to produce biotech therapies for human diseases. The company employed this breakthrough technology for a growing list of clients, including leading biotech companies, such as Amgen and Immunex, as well as for its own development of therapies for cancer and other diseases.